5406792026-04-012026-06-305406792026-04-012026-06-30in-capmkt:OtherExpenses1Member5406792026-04-012026-06-30in-capmkt:OtherExpenses2Memberiso4217:INRiso4217:INRxbrli:shares540679HALEOSLABSNOTLISTEDINE320X01016Haleos Labs LimitedMain BoardEquity2026-04-012027-03-312026-08-052026-08-01INRLakhsQuarterlyFirst quarterSingle segmentBulk Drugs / API's 2026-08-0512:30:002026-08-0513:45:00Not applicable2026-04-012026-06-30UnauditedConsolidated7294230004633000734056000401381000-136821000017549200018996000424450001981660006996590003439700003439700016000000-6000159940000184030000000184030004280001883100026466000-806300026801000-797000030233000108.758.75008.758.751. The above Consolidated Financial Results have been reviewed and recomended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026. The statutory auditors of the Company have carriedout limited review of Consolidated financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon. <br /> <br /> 2. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 (lithe Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 <br /> <br /> 3. The figures for quarter ended 31 st March , 2026 are balancing figures between audited figures of the full financial year ended 31 st March, 2026 and the published year to date figures upto third quarter ended 31st December, 2025, which were subjected to limited review by the statutory auditors <br /> <br /> 4. The Consolidated financial results are prepared by applying Ind AS-11 0 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary. <br /> <br /> 5. The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. <br /> <br /> 6. Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period' classification.Manufacturing Expenses156605000Other Expenses41561000-590000162000428000